The Prolyl Oligopeptidase Inhibitor KYP‑2047 Is Not Readily Bioavailable to Bloodstream Form Trypanosomes and Human Myelocytic Leukemia Cells. Journal of Pharmaceutical Negative Results 2015, 6 (1), 7-10.